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Cavernous vascular malformations occur with a frequency of 1:200 and can cause recurrent headaches,
seizures and hemorrhagic stroke if located in the brain. Familial cerebral cavernous malformations (CCMs)
have been associated with germline mutations in CCM1/KRIT1, CCM2 or CCM3/PDCD10. For each of the
three CCM genes, we here show complete localized loss of either CCM1, CCM2 or CCM3 protein expression
depending on the inherited mutation. Cavernous but not adjacent normal or reactive endothelial cells of
known germline mutation carriers displayed immunohistochemical negativity only for the corresponding
CCM protein but not for the two others. In addition to proving loss of function at the protein level, our
data are the ﬁrst to demonstrate endothelial cell mosaicism within cavernous tissues and provide clear
pathogenetic evidence that the endothelial cell is the cell of disease origin.
INTRODUCTION
Cerebral cavernous malformations (CCMs) are vascular
lesions causing chronic headaches, seizures and hemorrhagic
stroke. Autosomal dominantly inherited forms occur with a
frequency of 1:2000 to 1:10 000 and are associated with germ-
line mutations in one of at least three genes, CCM1, CCM2 or
CCM3. The occurrence of multiple CCMs in most hereditary
cases but only single CCM in the majority of sporadic cases
has led to the notion that biallelic mutations within the same
gene are required for the formation of CCMs (1,2). Such a
‘two-hit’ disease mechanism has been supported by the obser-
vation that slowly enlarging CCMs may develop as late seque-
lae of cranial radiation therapy within ﬁelds of prior irradiation
(3). However, a two-hit model of CCM genesis that assumes
inactivation of both alleles of a given CCM gene within
affected cells has been difﬁcult to prove. Biallelic germline
and somatic CCM1 mutations have thus far only been reported
once. Tissue pieces from the middle part of a single cavernous
lesion harbored a somatic 34 bp deletion within exon 15 of the
CCM1 gene in addition to a known CCM1 germline founder
mutation (4). Furthermore, two somatic CCM1 missense
mutations were found in a singular lesion of an individual
affected with sporadic CCM (5). While CCM1 mutations are
generally truncating or result from large genomic rearrange-
ments, the functional relevance of these two missense
mutations remained unclear. It could also not be determined
whether the two mutations occur in cis or in trans. Several
other groups have been unable to identify somatic mutations
in human and murine cavernous tissues (6–8). This may
have been due to the application of insensitive genetic screen-
ing techniques given that direct sequencing revealed many
CCM1 gene mutations that had been missed by denaturing
high-performance liquid chromatography or SSCP in the past.
A further explanation for the difﬁculties to prove the two-hit
model relates to the nature of the CCM tissue. Blood-ﬁlled,
often thrombosed and re-organized cavities are lined by extre-
mely thin endothelial cells that are separated by abundant col-
lagenous connective tissue containing a mixture of different
cell types (9). A putative second mutation could be envisioned
to occur only in a small subset of cells and, therefore, may
remain undiscovered during genetic screening.
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hybridization (5,10) and immunohistochemical studies (11)
have shown CCM transcript and protein expression in endo-
thelial and various non-endothelial cell types such as
neurons and astrocytes. Notably, cavernous malformations
do not only occur in the brain but occasionally also in the
skin (12) and consist of endothelial cells with slight prolifera-
tive tendency (13) and lack of endothelial tight junctions
(14,15) that stain positively with anti-CCM1 antibodies in
cell culture (16). Such morphologically altered, extremely
thin vascular endothelial cells lining the caverns appear to
be the primary disease compartment that needs to be
dissected and analyzed. This approach is supported by recent
transplantation experiments in zebraﬁsh that have shown that
ccm1 cell autonomously regulates endothelial cellular mor-
phology (17).
The present study demonstrates that a previously generated
anti-human CCM1 antibody (16) and two newly generated
anti-human CCM2 and CCM3 antibodies are immunohisto-
chemical markers for the vascular endothelium. CCM tissues
from individuals with known CCM1, CCM2 or CCM3 germ-
line mutations revealed that immunohistochemical negativity
of the corresponding CCM protein is the hallmark of vascular
endothelial cells lining pathological caverns. Lack of immu-
noreactivity of the respective CCM protein in cavernous endo-
thelial cells provides strong evidence for the two-hit
hypothesis of CCM formation and underscores the concept
of morphologically abnormal endothelial cells lining caverns
as targets of disease origin. In addition, our studies reveal
that the detection of loss-of-heterozygosity in CCM endo-
thelial cells is complicated by both low number of mutated
cells and the fact that the vascular endothelium within a
single CCM tissue is mosaic for wild-type and mutant endo-
thelial cells.
RESULTS
Variable expression of CCM proteins in normal brain
vascular endothelium
The newly generated anti-human CCM3 antibody reacts speciﬁ-
cally with a fragment of the size of 25 kDa recombinant human
CCM3 invarious human cell and murine tissue lysates (Fig. 1A)
andwithCCM3peptideMIERPEPEFQDLNEK(Fig.1B).Anti-
human CCM2 recognizes overexpressed CCM2 (Fig. 1C) as
well as several CCM2 epitopes (Fig. 1D) but could only be
used in high concentrations that yielded strong background in
most western blots with cell and tissue lysates. Immunohisto-
chemistry demonstrated that both antibodies and a polyclonal
but not a monoclonal anti-human CCM1 antibody (16) stained
vascular endothelium of venous, arterial and capillary blood
vessels (Fig. 2). The CCM1 antibody demonstrated immuno-
reactivity in both meningeal (Fig. 2A) and parenchymal
vessels (Fig. 2B). We observed large differences of the staining
intensity for CCM1 among the endothelia of different normal
brain vessels and within the meninges. Parenchymal capillary
endothelia with broadened walls were often stained, whereas
vessels with narrow walls regularly showed no immunoreactiv-
ity. Moreover, brain tissue cells resembling microglia revealed
strong immunoreactivity (Fig. 2C). This correlated well to the
strong staining of foamy macrophages in the vicinity of a caver-
noma from a CCM2 germline mutation carrier (Fig. 2D). The
antibody against CCM2 revealed granular staining of capillary
vessels throughout the brain parenchyma and in the meninges
(Fig. 2E and F). The antibody against CCM3 showed a staining
patternsimilartoCCM1.Mostvesselendotheliawerelabeledby
the antibody (Fig. 2G). However, there were thin-walled
vessels that showed merely weak or no immunoreactivity
(Fig. 2F and G). In addition, the CCM3 antibody detected poly-
morphonuclear blood cells and Purkinje cells in the cerebellum
(Fig. 2G and H).
Absence of CCM immunoreactivity in endothelial cells
lining pathological caverns correlates with the respective
CCM germline mutation
Markedly reduced to absent CCM1 immunostaining in endo-
thelial cells lining pathological caverns was observed for
cavernous endothelia analyzed from one patient carrying a
CCM1 germline mutation (No. 1, Table 1, Supplementary
Material, Fig. S1A). Within the cavernous lesion of a second
individual with a CCM1 germline mutation (No. 2, Table 1),
a subset of presumably neoangiogenic vessels was labeled
with the anti-CCM antibody (Fig. 3A) while endothelia
lining large pristine caverns were found to be immunonegative
for CCM1 (Fig. 3B). For this familial case 2, adjacent brain
tissue was available, which demonstrated prominent staining
of normal arterial endothelium with the anti-human CCM1
antibody on the same tissue section (data not shown).
Caverns analyzed from both CCM1 germline mutation carriers
(Table 1, Nos 1 and 2) showed positive immunostaining for
CCM2 and CCM3 (Supplementary Material, Figs S1B and C
and Fig. 3C, D). Consistent with our recent ﬁnding that
expression of CCM1:p.A715VfsX14 is reduced but not
absent in vitro (18), even pristine caverns from sporadic
case No. 3 (Table 1) demonstrated weak immunoreactivity
(Supplementary Material, Fig. S1D).
Immunohistochemical negativity of cavernous endothelial
cells from three carriers of CCM2 germline mutations that
are all located near the 50 end of the CCM2 gene (Table 1,
Nos 4–6) was consistent with defective CCM2 protein
expression in all cavernous endothelia assessed (Fig. 3F, Sup-
plementary Material, Fig. S1H and K). In contrast, regular
brain arterial endothelium (available for individual Nos 4
and 5) showed immunoreactivity with the anti-human CCM2
antibody (Fig. 3E). As expected, cavernous endothelium
from carriers of CCM2 germline mutations stained positively
for anti-human CCM1 and CCM3 antibodies (Fig. 3G and
H, Supplementary Material, Fig. S1G, I, J and L).
CCM3 mutations are known to account for only 10% of
CCM mutations (18,19). The only individual with a germline
mutation in the CCM3 gene in our panel of patients (Table 1,
No. 7) showed absent CCM3 expression in cavernous endo-
thelial cells (Fig. 3J), whereas capillary endothelial cells of
vessels in revascularized thrombosed caverns within the
same tissue sections reacted with the anti-human CCM3 anti-
body (Fig. 3I). Again, endothelial cells lining pathological
caverns of the CCM3 germline mutation carrier revealed
immunoreactivity for CCM1 and CCM2 (Fig. 3K and L).
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sponding CCM protein in endothelia from CCM tissues har-
boring a germline mutation suggests that the antibodies
tested speciﬁcally stain the corresponding CCM1, CCM2 or
CCM3 proteins. Furthermore, our data underline that CCM
pathology is primarily due to defective endothelial cells.
Most importantly, complete and speciﬁc lack of CCM
protein in affected endothelial cells from CCM germline
mutation carriers supports a genetic two-hit mechanism for
CCM formation.
Technical limitations of genetic proof of two-hit
mechanism
For molecular analyses, about 200 morphologically pathologi-
cal endothelial cells (as seen in Fig. 3B) from each of three
small heterogeneous CCM1-3 tissues (Table 1, Nos 2, 4 and
7) were sampled by laser-assisted microdissection in order to
circumvent allele drop-out problems. Whole genome ampliﬁ-
cation (WGA) of the isolated DNA was performed by
improved primer extension pre-ampliﬁcation PCR
(I-PEP-PCR) (20,21). Subsequent ampliﬁcation and direct
sequencing of the CCM gene for which a germline mutation
(18,22,23) and negative CCM protein expression had been
found revealed that only a subset of exons could be ampliﬁed
most likely due to fragmentation of the DNA in the archival
parafﬁn-embedded tissues. These ampliﬁcation products did
not reveal a second somatic mutation.
DISCUSSION
Arteriovenous (ENG/ACVRL1/RASA1), venous (TIE2), glo-
muvenous (glomulin) and cavernous (CCM1, CCM2,
CCCM3) malformations are localized defects of vascular
development that have been associated with autosomal domi-
nantly inherited heterozygous germline mutations. Apart from
TIE2 mutations, all are thought to cause loss of function (24).
Paradominant inheritance was ﬁrst shown for glomuvenous
malformations (GVMs), which are characterized by abnor-
mally differentiated smooth muscle cells in the walls of dis-
tented venous channels. A somatic 5 bp deletion in the
second glomulin allele was identiﬁed in only one out of
seven resected fresh–frozen lesions from different individuals
by SSCP and heteroduplex analyses followed by sequencing
of the cloned ampliﬁcation product. It was concluded that cel-
lular heterogeneity of GVMs limits somatic mutation detection
(25). Similarly, a subtle denaturing high-performance liquid
chromatography change in only two out of three samples
from one surgically excised CCM lesion led to the identiﬁ-
cation of a biallelic somatic 34 bp deletion in the CCM1
gene. Peak heights suggested that 13.5–21% of DNA
derived from an unknown cell type in the middle of the
lesion carried the mutation, whereas the mutation-negative
Figure 1. (A) Polyclonal anti-human CCM3 antibody speciﬁcally reacts with a protein of the size of recombinant human CCM3 puriﬁed from E. coli (lane 1) in
the indicated human cell and murine tissue lysates (HUVEC, human umbilical vein endothelial cells; HMEC, human microvascular endothelial cells; HeLa,
human epitheloid cervix carcinoma cells; 293, human embryonal kidney cell line). Ten micrograms of lysates was separated on 10–20% polyacrylamide–
SDS gradient gels and analyzed by western blotting. (B) CCM3 epitope mapping using PepSpots
TM technology. (C) Polyclonal anti-human CCM2 antibody
recognizes recombinant human CCM2 puriﬁed from E. coli, HA-tagged CCM2 as well as HA-tagged CCM2:p.P11_K68del (18) overexpressed in 293 cells
and a protein of the size of CCM2 in lymphocyte lysates. (D) CCM2 epitope mapping using PepSpots
TM technology. Peptide 11 resides within the PTB
domain making cross-reactivity likely. Peptide 56 was artiﬁcially modiﬁed and corresponds to peptide 34.
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posed of normal vessels (4). Our data deﬁne cavernous endo-
thelial cells as the primary disease compartment and suggest
that the mutation-negative vessels might correspond to
immunopositive neoangiogenic vessels as seen in
Figure 3I. In a recent systematic study of fresh–frozen
venous malformation tissues, single and double-hit mutations
in the angiopoietin-receptor gene TIE2 were found to cause
both solitary and multiple sporadic forms (26).
In contrast to the venous and glomuvenous skin lesions,
CCMs are less accessible and often resected at late stages
after recurrent bleeding. In addition, microsurgical excision
is performed by the dissection of the vessel to brain interlayer.
During the excision, the cavernous lesion itself and the feeding
Figure 2. Expression of CCM proteins in human brain tissues. (A) Polyclonal anti-human CCM1 antibody stains vascular endothelia (arrowheads) in normal
meningeal tissues. The asterisks indicate an adjacent blood vessel with immunonegative endothelial cells. (B) Stronger (arrowhead) and weaker (asterisk) stain-
ing intensities with the anti-CCM1 antibody in parenchymal vessels. The CCM1 antibody also stains (C) microglia and (D) foamy macrophages in the vicinity of
a cavernous lesion. (E) Granular staining of capillary vessels in the brain parenchyma (E) and the meninges (F) incubated with the polyclonal anti-human CCM2
antibody. (G and H) Positive immunoreactivity of vessel endothelia with the polyclonal anti-human CCM3 antibody which also detected (G) polymorphonuclear
blood cells (arrow) and (H) Purkinje cells (arrow) in the cerebellum. (G) Similar to anti-CCM1, anti-CCM3 shows different staining intensities for endothelia of
vessels with broadened walls (arrow head) when compared with adjacent thin-walled vessels (asterisk).
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No. Presentation Gene Exon Nucleotide change Amino acid
change
Type of
mutation
Reference CCM1-IH CCM2-IH CCM3-IH
1 Familial CCM1 16 c.1683_1684insA p.V562SfsX6 Frameshift (22) 2 þþ
2 Familial CCM1 17 c.1780_1783delinsTA
CCTGTTACCAAA
p.A594YfsX14 Frameshift (23) 2
a þþ
3 Sporadic CCM1 Intron19 c.2143-2A.G p.A715VfsX14 Splice (18) (þ)
b þþ
4 Familial CCM2 Intron1 c.30þ1G.A p.? Splice (18) þ 2 þ
5 Familial CCM2 2 c.55C.T p.R19X Stop (18) þ 2 þ
6 Familial CCM2 2 c.55C.T p.R19X Stop (18) þ 2 þ
7 Familial CCM3 7 c.350_351insT p.D119RfsX2 Frameshift (18) þþ2
a
IH, immunohistochemistry of CCM endothelial cells. Nos 5 and 6 are siblings. GenBank accession nos are: CCM1: NM_194456.1, CCM2:
NM_031443.3, CCM3: NM_007217.3. DNA mutation numbering is based on cDNA sequence with þ1 corresponding to the A of the ATG translation
initiation codon.
aImmunonegative pristine caverns plus immunoreactive endothelial cells within same CCM lesion, the latter most likely representing neoangiogenic vessels
derived from vessels with only the germline mutation.
bPartial immunoreactivity in pristine caverns corresponding to the fact that CCM1:p.A715VfsX14 was shown to be reduced but not absent in vitro (18).
Figure 3. Serial sections from carriers of a known germline mutation in one of the three CCM genes immunostained for CCM1, CCM2 and CCM3, respectively.
Immunohistochemistry with the anti-human CCM1 antibody revealed (A) CCM1-positive and (B) CCM1-negative endothelia (arrowheads) within the same
cavernous malformation tissue section of a CCM1:c.1780_1783delinsTACCTGTTACCAAA germline mutation carrier (Table 1, No. 2), whereas (C) CCM2-
and (D) CCM3-immunoreactivity was observed. (E) Normal brain arterial endothelium of a CCM2:c.30þ1G.A germline mutation carrier (Table 1, No. 4)
reacts with the anti-human CCM2 antibody while (F) cavernous endothelium in the same tissue section does not. (G and H) Immunostaining for CCM1 and
CCM3 is positive in caverns from this individual. (I) Vessels in revascularized thrombosed caverns of a CCM3:c.350_351insT germline mutation carrier
(Table 1, No. 7) show CCM3-immunoreactivity, whereas (J) pristine caverns do not. (K and L) Positive immunostaining for CCM1 and CCM2 in the same
cavernous lesion. Scale bar in (A): 100 mm, in (E): 20 mm, all others: 50 mm. Insets in (C) and (L) demonstrate faint granular immunoreactivity for CCM2,
whereas the inset in (F) shows negativity for CCM2 at ﬁve times higher magniﬁcation (original magniﬁcation 100 ).
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cal coagulation. Thus, the CCM tissue is often primarily
thrombosed, reorganized, calciﬁed and always artiﬁcially
altered by the surgical manipulation. Furthermore, endothelial
cells lining pristine caverns only represent a small subset of
cells. Therefore, DNA must be puriﬁed from small amounts
of laser-microdissected starting material and pre-ampliﬁed
by WGA to enrich mutant cells. When implementing WGA
in our laboratory, only archival parafﬁn-embedded tissues
were available for our cohort of patients. Compared with
frozen sections, the quality of cell morphology for immunohis-
tochemistry and laser microdissection is superior. However,
ﬁxation and staining procedures as well as sampling and
storage conditions are known to compromise the integrity of
the DNA and present a challenge for molecular analyses.
Several WGA techniques are not suitable for use with
formalin-ﬁxed, parafﬁn-embedded clinical samples due to
fragmentation of the template genomic DNA. For
parafﬁn-embedded tissue sections, I-PEP-PCR was previously
shown to yield the most efﬁcient downstream ampliﬁcation
results after pre-ampliﬁcation (20) but did not lead to detection
of mutations in our tissue samples. Thus, the nature of the
second-hit event remains unknown and potentially includes
small mutations, large inactivating gene deletions (27–30),
epigenetic as well as (post-)transcriptional pathomechanisms.
Endothelial cell mosaicism within CCM tissues as seen in
Figure 3A and I represents a further problem for molecular
analyses. CCMs have been characterized as hamartomatous
since they are benign, disorganized lesions with growth poten-
tial as a result of proliferative capacity and hemodynamic
modiﬁcations. Endothelial proliferation and neoangiogenesis
has been demonstrated within human CCM specimens by
immunohistochemical staining for proliferating cell nuclear
antigen (PCNA) and various vascular markers (13,31).
Notelet et al. distinguished between areas with collagenous,
thick-walled caverns and very few PCNA-stained endothelial
cells and ‘territories showing irregular, dilated, closely contig-
uous vascular spaces separated by lacy walls often with
stained endothelial cells’ as seen in Figure 3B or L. They
also noted thrombi with ﬁgures of revascularization that con-
tained PCNA-positive cells as well as staining of endothelial
cells in capillaries at the periphery of these lesions and reac-
tive glial cells, endothelial cells and pericytes in the surround-
ing brain parenchyma. Thus, the majority of activated
proliferating endothelia within CCM tissues appears to be
reactive and to correspond to the CCM-immunopositive
neoangiogenic vessels seen in our study (Fig. 3A and I).
Experimental data from zebraﬁsh knockdown and knockout
studies suggest alterations in endothelial cell morphology rather
than endothelial cell proliferation as likely pathomechanism
(17). We have observed that thick-walled thrombosed caverns
often even lack endothelial cells at the cavernous wall (data not
shown). It is conceivable that biallelic loss of a CCM-coding
gene might affect other than tumor suppressor functions of
CCM interactors like RAPIA, e.g. regulation of endothelial
cell-cell junctions (16). Therefore, somatic inactivation of the
TIE2, CCM and glomulin genes suggests that the Knudsonian
two-hitmechanismmaynotbelimitedtoaclassictumorsuppres-
sormodelbutalsoplaysapivotalroleinthepathogenesisofthese
non-neoplastic vascular malformations.
MATERIALS AND METHODS
Generation of antibodies against human CCM2 and CCM3
Full-length human CCM2 and CCM3 genes were cloned into
pET28b and overexpressed in Escherichia coli strain BL21
(DE3), respectively. Highly puriﬁed protein samples were
obtained by IMAC capture of His-tagged fusion proteins using
Ni-NTA superﬂow matrix (Qiagen), subsequent thrombin pro-
teolysis of the His-tag followed by a subtractive IMAC step to
remove uncleaved protein and a ﬁnal gel ﬁltration step on a pre-
parativeSuperdex75column(GEHealthcare)(CRELUXGmbH,
Martinsried,Germany).Thepuriﬁedproteinswerepureasjudged
by SDS–PAGE analysis and Coomassie staining. Polyclonal
anti-human CCM2 and anti-human CCM3 sera were prepared
through the immunization of rabbits with puriﬁed human
CCM2 or CCM3 proteins coupled to keyhole limpet hemocyanin
(immunoGlobe GmbH, Himmelstadt, Germany). Sera were afﬁ-
nity puriﬁed on columns consisting of non-tagged CCM2 or
CCM3 protein covalently coupled to NHS–Sepharose 4FF
beads. Western blot analyses of various tissue and cell lysates
demonstrated that the anti-human CCM3 antibody reacted with
a speciﬁc 25 kDa band as well as an additional 70 kDa protein
representing Hsp70 and 30S ribosomal protein S1 as determined
by mass spectrometry (data not shown). To get rid of these con-
taminations, epitope mapping of the 212 amino acid CCM3
sequence was carried out using PepSpotsTM technology (JPT
Peptide Technologies GmbH, Berlin). Two libraries of 15mer
peptides with eight or nine amino acids overlap revealed MIER-
PEPEFQDLNEKasamajorepitope.Inanalternativeapproach,a
peptide corresponding to this sequence was used for puriﬁcation
oftheanti-CCM3antiserumyieldinganafﬁnity-puriﬁedantibody
(IG-626; immunoGlobe GmbH,Himmelstadt, Germany) speciﬁc
to human, murine, rat, chicken and Xenopus CCM3. The respect-
ive peptide from Danio rerio is not recognized by this antibody
(data not shown). The PepSpots
TM technology was also applied
for CCM2 epitope mapping. However, due to the extremely
low yield of the peptide-puriﬁed anti-CCM3 antibody, this
approach was not pursued for the anti-CCM2 antibody that
proved to work speciﬁcally in immunohistochemical appli-
cations.
Western blotting
Cell lysates were prepared as described by Voss et al. (32).
Mouse tissues were homogenized in an iso-osmotic homogen-
ization buffer (0.25 M sucrose, 10 mM Tris pH 7,2, 1 mM
EDTA, Roche complete EDTA-free protease inhibitor) by
ﬁve passes with 1000 U/min using a Potter S homogenizer
(5). After a centrifugation step of 1000 r.p.m. for 2 min
(rotor F45-30-11, eppendorf, Hamburg), the post-nuclear
supernatants were frozen in liquid nitrogen. Cell lysates
were prepared with lysis buffer (1% Triton-X-100, 10 mM
Tris pH 8, 1 mM EDTA, Roche complete EDTA-free protease
inhibitor). For western blot analysis, 10 mg of tissue and cell
lysates were loaded onto 10–20% SDS–PAGE gels, electro-
blotted onto nitrocellulose and probed with the polyclonal
rabbit anti-human CCM3 antibody at a dilution of 1 mg/ml.
Secondary antibodies conjugated to peroxidase were pur-
chased from Dianova.
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Immunohistochemistry was performed on neutral-buffered
formalin-ﬁxed and parafﬁn-embedded tissue slices as
described before (33). Brieﬂy, tissue sections (3 mm) were
deparafﬁnized in xylene and rehydrated in graded alcohol.
Antigen retrieval was performed in citrate buffer (pH 6.0) in
a standard microwave oven for 10 min followed by blocking
the endogenous peroxidase with H2O2 (3%) in methanol and
blocking unspeciﬁc antibody binding with goat normal
serum. Polyclonal anti-human CCM1 antibody (pAB
anti-KRIT-1, Rb6832), a kind gift of Drs Marc Ginsberg and
Angela Glading (University of California, San Diego), anti-
human CCM2 antibody and anti-human CCM3 antibody
were used at a dilution of 1:1000 (16) or concentrations of
16 and 6 mg/ml for immunohistochemistry, respectively.
Antigen binding was visualized with the Histostain-Plus kit
(Zymed Laboratories, South San Francisco, CA, USA).
Laser-capture microdissection, WGA and mutation
analyses
Laser-capture microdissection of 10 mm CCM tissue sections
was performed with a Leica LMD6000 microscope. Tissue
slices were deparafﬁnized, rehydrated in graded alcohol and
stained with 4,6-diamidino-2-phenylindole dihydrochloride at
a concentration of 400 ng/ml for 10 min in order to visualize
the nuclei of endothelial cells for microdissection.
Genetic testing was approved by local Ethics Committees
(University of Wu ¨rzburg, Study 21/05; Philipps-University
Marburg, Study 149/05) and performed with informed
consent. Published protocols were followed for DNA isolation
of about 200 endothelial cells per tissue (20) and WGA by
I-PEP-PCR (21). Subsequently, coding CCM1-3 exons includ-
ing adjacent splice sites were directly sequenced on a
Beckmann CEQ 8800 capillary electrophoresis system accord-
ing to (18).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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